CF PharmTech, Inc. disclosed a share buy-back on 26 May 2026, acquiring 67,500 H-shares on the Hong Kong Stock Exchange.

The repurchase was executed within a price range of HK$18.90 to HK$20.38 per share, resulting in a volume-weighted average price of HK$20.06 and an aggregate consideration of HK$1.35 million. All repurchased shares will be held as treasury shares.

Following the transaction, issued shares excluding treasury stock decreased from 301.22 million to 301.16 million, while treasury shares rose to 1.07 million. The total issued share count remained unchanged at 302.22 million. The one-day reduction represents 0.02 % of the shares outstanding before the buy-back.

The purchase was made under the company’s repurchase mandate approved on 16 December 2025, which authorises the repurchase of up to 30.22 million shares. To date, 1.07 million shares have been bought back, equating to 0.35 % of the share base at the mandate date. A moratorium on new share issues or treasury-share disposals is in effect until 25 June 2026.

Management confirmed that the transaction complied with all applicable Hong Kong Listing Rules and relevant regulatory requirements.